Goldsmith, Scott
348  results:
Search for persons X
?
3

P-264 A phase 1b study of isatuximab and bendamustine for t..:

Goldsmith, Scott ; Slade, Michael ; Fiala, Mark...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S181 , 2023
 
?
4

P-131 Daratumumab (dara) as maintenance therapy after autol..:

Borogovac, Azra ; Pichiorri, Flavia ; Matous, Jeffrey...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S107-S108 , 2023
 
?
5

P-265 Mezigdomide (MEZI) monotherapy in relapsed/ refractor..:

Goldsmith, Scott ; Oriol, Albert ; Anttila, Pekka...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S181-S182 , 2023
 
?
7

P-347 Longitudinal profiling identifies genetic mechanisms ..:

Keats, Jonathan ; Borogovac, Azra ; Kyman, Shari...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S230-S231 , 2023
 
?
9

L-type amino-acid transporter 1 (LAT1) expression is predic..:

Fiala, Mark ; Goldsmith, Scott ; Hathi, Deep...
Clinical Lymphoma Myeloma and Leukemia.  19 (2019)  10 - p. e63-e64 , 2019
 
?
10

Multiple Myeloma: Autologous Stem Cell Transplant in an agi..:

King, Justin ; Fiala, Mark ; Goldsmith, Scott...
Clinical Lymphoma Myeloma and Leukemia.  19 (2019)  10 - p. e293-e294 , 2019
 
?
 
?
12

Downregulation of the unfolded protein response is a potent..:

Goldsmith, Scott ; Fiala, Mark ; Schroeder, Mark...
Clinical Lymphoma Myeloma and Leukemia.  19 (2019)  10 - p. e105 , 2019
 
?
14

The Economic and Social Impacts of the Permanent Fund Divid..:

, In: Alaska's Permanent Fund Dividend,
Goldsmith, Scott - p. 49-63 , 2012
 
1-15
Related subjects